biostudies-literaturede Boer IHNCATS NIH HHSNHLBINIDDK NIH HHSNCRR NIH HHSNHLBI NIH HHS106318https://www.ebi.ac.uk/biostudies/studies/S-EPMC8089051biostudies-literatureUnknown103The INdividual response to VITamin D (INVITe) trial was a randomized, placebo-controlled, parallel group trial of vitamin D₃ supplementation (2000 IU daily) designed to determine clinical and genetic characteristics that modify the response to vitamin D supplementation. To enhance internal and external validity and reduce cost, the INVITe trial was nested within the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing prospective observational cohort study. The INVITe trial enrolled a community-based population of 666 racially and ethnically diverse participants from January 2017 to April 2019. This represents 30% of 2210 MESA participants approached for screening, and 96% of those found to be eligible. Barriers to enrollment included delayed initiation of the trial relativeContemporary clinical trialsThe Multi-Ethnic Study of Atherosclerosis individual response to vitamin D trial: Building a randomized clinical trial into an observational cohort study.PMC8089051UL1 TR001420UL1 TR001881R01 HL071205UL1 RR033176N01HC9515975N92020D00007UL1 RR02500575N92020D0000175N92020D00002T32 DK007467P30 DK03581675N92020D0000575N92020D0000675N92020D0000375N92020D00004UL1 TR000040R01 HL096875HHSN268201500003CR01 HL071259N01HC95160R01 HL071258UL1 TR001079N01HC95161N01HC95162N01HC95163P30 DK017047N01HC95164N01HC95165R01 HL071051N01HC95166R01 HL071251N01HC95167N01HC95168R01 HL071250N01HC95169R01 HL071252R01 DK088762R01 DK099199HHSN268201500003IWatson KEPsaty BMHoofnagle ANRotter JIRice KMWilliams KSiscovick DSLiu KJBurke GLAllen NBHsu SLi XPrince DKde Boer IHMichos EDTracy RPKestenbaum BRMcClelland RLShea SJfalseThe Multi-Ethnic Study of Atherosclerosis individual response to vitamin D trial: Building a randomized clinical trial into an observational cohort study.The INdividual response to VITamin D (INVITe) trial was a randomized, placebo-controlled, parallel group trial of vitamin D₃ supplementation (2000 IU daily) designed to determine clinical and genetic characteristics that modify the response to vitamin D supplementation. To enhance internal and external validity and reduce cost, the INVITe trial was nested within the Multi-Ethnic Study of Atherosclerosis (MESA), an ongoing prospective observational cohort study. The INVITe trial enrolled a community-based population of 666 racially and ethnically diverse participants from January 2017 to April 2019. This represents 30% of 2210 MESA participants approached for screening, and 96% of those found to be eligible. Barriers to enrollment included delayed initiation of the trial relative2021-01-01T00:00:00Z2021 Apr2025-04-04T23:02:24.135Z2025-04-04T23:02:24.135ZS-EPMC80890513358807810.1016/j.cct.2021.106318